Sciwind Biosciences Announces Global Licensing And Collaboration Agreement For Metabolic Disease Portfolio
(MENAFN- PR Newswire) HANGZHOU, China, Jan. 10, 2025 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., a pre-commercial biopharmaceutical company focusing on developing innovative therapies to treat metabolic diseases, today announced a licensing …